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Introduction
An estimated 627,000 malaria deaths
occurred in 2012, mostly in African
children and many of them preventable
with prompt diagnosis and treatment [1].
Access to diagnosis remains poor—in half
of endemic African countries, over 80% of
malaria treatments are applied without
diagnostic testing [2]. Improving diagnosis
and treatment of malaria will improve
treatment outcomes, rationalize health
care costs by reducing drug consumption
[3], minimize drug pressure that can
contribute to resistance [4,5], and assist
in monitoring disease trends [2].
In April 2012, the World Health
Organization’s (WHO) Global Malaria
Programme launched a highly ambitious
new initiative: T3: Test. Treat. Track [1,2].
T3 aims to address the widespread prob-
lem of poor access to diagnostic testing
and antimalarial treatment, and to en-
hance case-reporting. It sets a target of
universal access to diagnostic testing in the
public and private health care sector by
2015 [1,2]. Achieving this goal will centre
on the use of malaria rapid diagnostic tests
(RDTs).
In this Policy Forum article we examine
the operational challenges to implement-
ing the T3 strategy of scaling up and
maintaining RDT coverage. We identify
gaps in planning for at-scale implementa-
tion in policy design and implementation,
the local health care setting, and the
attitudes and demands of patients. While
focussed on malaria diagnosis and treat-
ment, the challenges illustrated here are
not unique to malaria and may apply to
health care provision across resource-poor
settings.
Policy Design and
Implementation
By 2012, 41 out of 44 endemic countries
in the WHO African Region had adopted
the policy of providing malaria diagnostic
testing for all age groups before treatment
[2]. RDT procurement increased world-
wide from 45 million units in 2008 to 205
million in 2012 although supply remains
far short of requirements [1,2]. In theory,
the availability of reliable easy-to-use tests
should result in a switch from presumptive
treatment based on signs and symptoms
alone, to parasite-based diagnosis and
treatment based on test results. Diagnostic
processes and treatment decisions are,
however, often irrational and health staff
do not always test the right patients, nor
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Summary Points
N Scaling up and sustaining access to malaria diagnosis and treatment in all
public sector, for-profit, and informal health facilities across sub-Saharan Africa
is central to current global strategies for malaria control and elimination.
N The use of malaria rapid diagnostic tests (RDTs) aims to eliminate reliance on
signs and symptoms to diagnose and treat malaria but evidence shows health
workers do not always test the right patients, nor provide treatment based on
the results of the test.
N Expanding access to malaria RDTs on the scale needed to achieve universal
coverage requires retraining of public, private, and retail sector providers as
well as sustained supplies and quality assurance.
N Barriers to rational use of tests and drugs may be overcome through
appropriate policy design for the local health service setting, which addresses
health worker practice and patient perceptions.
N Innovative methods have been used to increase access to the most effective
antimalarial drugs in the last five years, but these efforts will be incomplete and
unsustainable without similar efforts to incorporate RDTs into practice.
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provide treatment based on the results [6–
8].
RDTs will be introduced in health
facilities and among community health
workers (CHWs) who work at local levels.
To translate the change in policy to a
change in routine practice where tests are
appropriately used by providers, unambig-
uous messages and guidelines that are
adapted to the local context are needed
[6,9,10]. This targeted information must
counter the widespread and long-held
guidelines that promoted presumptive
treatment of malaria in cases of fever
[11]. Appropriate information and training
will improve implementation at the com-
munity level [12]. Recent evidence shows
that CHWs reliably provided Integrated
Management of Childhood Illnesses to
children after training and incorporation
of RDTs into the algorithm [13,14]. In one
study, malaria and pneumonia were ap-
propriately classified in 94%–100% of
children, and supply management of med-
ications and RDTs was excellent [13].
Replicating these effects outside the trial
setting requires national level training to
ensure safety and quality of services.
Mobilising sufficient resources for the
training and monitoring required to sus-
tain the new policy is the key to success.
A reliable system for RDT delivery needs
to include re-training of staff and consis-
tent quality assurance at all levels. The
quality of services is likely to wane over
time and can be aggravated by high
staff turnover, which occurs in many
health service settings. Ensuring pro-
gramme quality and sustainability there-
fore requires constant rolling interventions
and local evidence for the best models of
implementation.
The Local Health Care Setting
In the local health care setting, two
problems persist: firstly, parasite-based
testing is generally unavailable [1,2] with
treatment decisions based on clinical signs
and symptoms that are neither sensitive
nor specific [15]; and secondly, if tests are
available, health workers often do not
apply treatment according to the result of
the test [10,16–18]. Both situations result
in extensive overuse of antimalarial drugs,
especially in low transmission settings
[19,20].
When RDTs are introduced in pre-
sumptive treatment settings significant
reductions in the overprescription of
antimalarials have been seen in almost all
studies published (Table S1). However,
when they are introduced in settings that
have used microscopic examination of
blood smears, the advantages of RDTs
are harder to define. Substantial numbers
of patients may still be treated with an
antimalarial drug despite a negative RDT
or blood smear result, so the evidence of
any clinical advantage of RDTs over
microscopy is unclear in some settings
(Table S2).
Often, the irrational use of tests and
drugs is based on perceived shortcomings
of the tests. A common concern amongst
health staff is that negative tests do not
definitively rule out malaria [21], but trials
that withheld antimalarials in febrile
children with negative test results have
shown no additional malaria risk to
patients in moderate-to-high transmission
settings. In one trial in Uganda, 13/1,602
(0.8%) blood smear–negative patients who
were not given antimalarial drugs devel-
oped clinical malaria over 7 days of follow-
up and all 13 were detected by the health
service and treated [22]. Similar findings
were seen in Tanzania (3/603 [0.5%] of
RDT-negative patients developed malaria
within 7 days) [23]. These studies indicate
that withholding antimalarial therapy in
febrile children with negative test results
is likely to be safe and results in a con-
siderable reduction in antimalarial drug
consumption.
Improvements in antimalarial prescrip-
tion often coincide with increases in
prescription of antibiotics amongst test-
negative patients. All studies where anti-
malarial prescription rates were reduced in
malaria-negative patients show an increase
in antibiotic prescriptions (Tables S1 and
S2) [16,19,24–26]. There is little data on
the spectrum of infections in patients
presenting with symptoms of suspected
malaria but most of these are probably
self-limiting [23,27], and evidence that
supports the prevailing practice of wide-
spread antibiotic use in malaria negative
patients is lacking.
Identifying patients at risk of progress-
ing to severe disease in which antibiotic
treatment and/or referral would have a
clinical advantage, while withholding an-
tibiotic treatment in other patients, is a
considerable challenge. Affordable rapid
diagnostics for bacterial infections or
markers of severe infections would support
the rational prescription of both antima-
larials and antibiotics.
Patient load and malaria diagnosis
A high patient load in many clinics
creates challenges in implementing new
policies and motivating staff [28,29]. In
Tanzania, health workers identified high
patient load and shortage of staff as key
factors that hindered use of RDTs [28].
Most staff felt RDTs placed additional
strain on normal operations and believed
more staff were needed to conduct the
tests [28]. Although these considerations
apply to all diagnostic procedures and are
not unique to RDTs, understanding the
realities of routine practice is required
because introducing extra staff into facil-
ities will have an impact on cost.
Sustained supply of RDTs in public
and private sectors
Sustaining the supply of RDTs is a
substantial challenge. In rural areas, where
access to services is often low but demand
for services may be highest [1], drug stock-
outs are common [30,31] and supply is one
of the biggest challenges facing the health
system. The T3 recommendations imply
that a constant supply of both artemisinin-
based combination therapies (ACTs) and
RDTs is needed. The shelf-life and perfor-
mance of both diagnostics and drugs
depends on their storage conditions; RDTs
are degraded by high temperatures and
humidity and the entire supply chain must
ensure that RDTs remain within manufac-
turers’ recommended limits. WHO testing
of a range of commercially available RDTs
demonstrated consistent detection of ma-
laria at tropical temperatures [21], but
actual field data on storage conditions
affecting RDT stability are scarce.
The private for-profit sector plays an
important role in delivering services across
most of Africa and the majority of
suspected malaria episodes are initially
treated by private health workers [32,33].
Data from a limited number of countries
suggest neither microscopy nor RDTs
have penetrated the private health care
sector [1,34] but more than 50% of
patients purchase drugs from unregistered
shops and peddlers [32,33]. This occurs
especially amongst lower income groups
[35]. Improving diagnostic and treatment
practices in the private sector could have a
substantial impact on access to diagnosis
before treatment but models of implemen-
tation have yet to be fully assessed in
operational trials [35,36].
Affordability and cost-effectiveness
of RDT-based diagnosis
To improve access to drugs in sub-
Saharan Africa, the Affordable Medicines
Facility - malaria provided subsidised ACT
drugs in a multi-country pilot [37]. This
study demonstrated improved access and
market share of ACTs in five out of seven
pilot countries driven mainly by improve-
ments in the private for-profit sector [38].
In 2012, 331 million courses of ACTs were
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procured by the public and private sectors
in endemic countries, up from 182 million
in 2010 [1]. Although the pilot rapidly
improved availability, affordability, and
market share of quality-assured ACTs at
the point of use, no equivalent increase in
RDTs has been observed [1,38]. As diag-
nosis is seldom available and ACT orders
are more than double that of RDTs,
overtreatment is likely to be common in
retail outlets. ACTs are approximately ten
times more costly than previously used
monotherapies [19,31] so the use of RDTs
prior to treatment may improve cost-
effectiveness. Data from a willingness-to-
pay study in private drug shops in Uganda
indicated that there was a demand for
RDTs in the private sector but this was far
below the price of delivery [39]. Subsi-
dised supply of RDTs, similar to the ACTs
subsidy, should be assessed to examine the
impact on the uptake of RDTs in the
private retail sector.
In high and very high transmission
areas, presumptive treatment has cost-
effectiveness advantages given the imper-
fect sensitivity of tests under field condi-
tions [3]. RDTs in settings with up to 62%
Plasmodium falciparum prevalence were
cost-effective compared to presumptive
treatment, assuming that prescribers ad-
hered fully to test results [31]. When
treatment is consistent with the results of
a test, cost savings of between 50% and
100% can be achieved compared with
presumptive treatment [3]. Conversely, if
treatment is inconsistent with the result of
the test, cost-effectiveness is reduced, an
association that varies with the malaria
transmission setting [3,31]. Other factors
that can reduce cost-effectiveness are
stock-outs, poor accuracy of RDTs, and
poor quality assurance for drugs and
diagnostics [31].
In low-endemic settings, RDTs and
microscopy remain attractive compared
to presumptive treatment even when there
is poor adherence to negative test results
[3]. RDTs can be more cost-effective than
microscopy because they are more accu-
rate under real-life conditions [31] and
continuous (re-)training of microscopists
is particularly important if fewer malaria
positive slides with low parasite levels
are encountered in low-endemic settings.
Despite these advantages of RDTs over
presumptive treatment, adherence to mi-
croscopy and RDT test results remains a
key factor for cost-effective diagnosis and
treatment [3,40].
Malaria diagnosis in elimination
programmes
Currently available RDTs will not
detect all infections with low parasite
loads. These submicroscopic infections
frequently occur in low-endemic areas
[41], are probably not associated with
clinical risks [42], but do play a role in
onward malaria transmission [43]. Diag-
nostics with a sensitivity that is higher than
currently available RDTs will be needed
to identify all malaria infections in elimi-
nation efforts [44]. Operational approach-
es may involve screening by RDT to
identify geographic or demographic clus-
ters of infections [45,46] that can be
targeted following molecular diagnosis of
infection or by focal mass drug adminis-
tration [47,48].
Attitudes and Demands of
Patients
Patients can influence the diagnostic
and treatment practices of health workers
[7,8] and patient pressure on providers
contributes to overtreatment [7]. There is
a persistent perception that all fever
episodes in malaria endemic areas are
due to malaria [49] and, until recently, a
global policy of presumptive treatment for
malaria in cases of fever has been in place
[2]. These factors have created entrenched
demand for malaria treatment without
first testing for malaria [29,50,51]. Efforts
to change demands to promote malaria
testing are particularly important in the
private and informal sector, where few
patients presently receive a diagnostic test.
A change in public perceptions brought
about by effective communication is
needed to widen demand for testing before
treatment.
Conclusions
Meeting the global target of universal
coverage with parasite-based diagnosis by
2015 is a huge undertaking requiring
sufficient resources. The cost-effectiveness
of the intervention will hinge on the
accurate use of RDTs in guiding treat-
ment. Probably the biggest challenge in
RDT implementation will be to provide
adequate and sustained supplies of RDTs
and appropriate training to all health
workers in endemic areas. With increased
access to malaria diagnosis, there will also
be increased use of antibiotics, and
interventions to guard against even greater
overuse are needed to prevent worsening
antimicrobial resistance. The Affordable
Medicines Facility - malaria initiative demon-
strated that large increases in access to
ACTs were possible. Increasing access to
RDTs is equally important. ACTs and
RDTs should be seen as a package to
improve management of febrile cases, and
improving access to both of these in the
public and private sectors has the potential
to provide valuable returns.
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